Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Non-viral amplification systems for gene transfer: vectors based on alphaviruses.

C Smerdou1, P Liljeström

  • 1Microbiology & Tumor Biology Center, Karolinska Institute, Stockholm, Sweden. cristian.smerdou@mtc.ki.se

Current Opinion in Molecular Therapeutics
|November 22, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

T- and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates.

Gene therapy·2016
Same author

A coordinated cross-disciplinary research initiative to address an increased incidence of narcolepsy following the 2009-2010 Pandemrix vaccination programme in Sweden.

Journal of internal medicine·2015
Same author

A Semliki forest virus vector engineered to express IFNα induces efficient elimination of established tumors.

Gene therapy·2011
Same author

The SFV Gene Expression System.

Methods in molecular medicine·2011
Same author

Expression of proteins using Semliki Forest virus vectors.

Current protocols in molecular biology·2008
Same author

Relation between viral fitness and immune escape within the hepatitis C virus protease.

Gut·2005
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

Non-viral self-replicating vectors offer efficient gene delivery. DNA-based alphavirus vectors provide enhanced stability and immune response induction, eliminating DNA integration risks.

Area of Science:

  • * Virology
  • * Molecular Biology
  • * Immunology

Background:

  • * Non-viral self-replicating vectors utilize defective alphavirus genomes (e.g., Semliki Forest virus, Sindbis virus, Venezuelan equine encephalitis virus).
  • * These vectors facilitate gene delivery via naked RNA or DNA formulations.
  • * Recombinant alphavirus RNA can be synthesized in vitro using plasmids with alphavirus replicons under prokaryotic promoters (SP6 or T7).

Purpose of the Study:

  • * To evaluate the efficacy of non-viral self-replicating alphavirus vectors for gene delivery and immune response induction.
  • * To compare the performance of RNA-based versus DNA-based alphavirus vectors.
  • * To assess the safety profile regarding DNA integration into host chromosomes.

Main Methods:

  • * Development of alphavirus replicons for gene delivery.

Related Experiment Videos

  • * In vitro synthesis of recombinant alphavirus RNA from plasmids.
  • * In vivo administration of RNA and DNA alphavirus vectors for immunization.
  • * Assessment of humoral and cellular immune responses in animal models.

    • Main Results:

    • * Self-replicating alphavirus RNAs induce protective immune responses in vivo, attributed to high antigen expression.
    • * DNA-based alphavirus vectors demonstrate superior stability and lower production costs compared to RNA vectors.
    • * DNA-based alphavirus vectors, utilizing RNA polymerase II promoters, are more efficient than conventional plasmids in eliciting humoral and cellular immunity.
    • * Smaller DNA quantities are sufficient for immunization with DNA-based alphavirus vectors.
    • * Transient nature of alphavirus replicons prevents DNA integration into host chromosomes.

    Conclusions:

    • * Non-viral self-replicating alphavirus vectors are effective tools for gene delivery and vaccine development.
    • * DNA-based alphavirus vectors offer advantages in stability, cost-effectiveness, and immunogenicity.
    • * These vectors provide a safer alternative to conventional gene delivery methods by mitigating risks of genomic integration.